NCT00966641View on ClinicalTrials.gov

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Healthy Volunteers
Interventions
DRUG

Naproxen

Single orally administered dose of 500 mg naproxen

DRUG

PL 3100

Single orally administered dose of PL 3100 (500 mg naproxen)

Trial Locations (1)

77074

Houston Institute for Clinical Research, Houston

Sponsors

Lead Sponsor

PLx Pharma
All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

PLx Pharma

INDUSTRY